465 related articles for article (PubMed ID: 26439599)
1. Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer.
Metro G; Chiari R; Ricciuti B; Rebonato A; Lupattelli M; Gori S; Bennati C; Castrioto C; Floridi P; Minotti V; Chiarini P; Crinò L
Expert Opin Pharmacother; 2015; 16(17):2601-13. PubMed ID: 26439599
[TBL] [Abstract][Full Text] [Related]
2. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
Dempke WC; Edvardsen K; Lu S; Reinmuth N; Reck M; Inoue A
Anticancer Res; 2015 Nov; 35(11):5797-806. PubMed ID: 26504000
[TBL] [Abstract][Full Text] [Related]
3. Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors.
Wrona A; Dziadziuszko R; Jassem J
Cancer Treat Rev; 2018 Dec; 71():59-67. PubMed ID: 30366200
[TBL] [Abstract][Full Text] [Related]
4. Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy.
Dudnik E; Siegal T; Zach L; Allen AM; Flex D; Yust-Katz S; Limon D; Hirsch FR; Peled N
J Clin Neurosci; 2016 Apr; 26():46-9. PubMed ID: 26677785
[TBL] [Abstract][Full Text] [Related]
5. Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS.
Klempner SJ; Ou SH
Chin Clin Oncol; 2015 Jun; 4(2):20. PubMed ID: 26112806
[TBL] [Abstract][Full Text] [Related]
6. Systemic Treatment of Brain Metastases.
Waqar SN; Morgensztern D; Govindan R
Hematol Oncol Clin North Am; 2017 Feb; 31(1):157-176. PubMed ID: 27912831
[TBL] [Abstract][Full Text] [Related]
7. Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer.
Doherty MK; Korpanty GJ; Tomasini P; Alizadeh M; Jao K; Labbé C; Mascaux CM; Martin P; Kamel-Reid S; Tsao MS; Pintilie M; Liu G; Bradbury PA; Feld R; Leighl NB; Chung C; Shepherd FA
Radiother Oncol; 2017 May; 123(2):195-202. PubMed ID: 28363487
[TBL] [Abstract][Full Text] [Related]
8. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
Yang JJ; Zhou C; Huang Y; Feng J; Lu S; Song Y; Huang C; Wu G; Zhang L; Cheng Y; Hu C; Chen G; Zhang L; Liu X; Yan HH; Tan FL; Zhong W; Wu YL
Lancet Respir Med; 2017 Sep; 5(9):707-716. PubMed ID: 28734822
[TBL] [Abstract][Full Text] [Related]
9. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
Toyokawa G; Seto T; Takenoyama M; Ichinose Y
Cancer Metastasis Rev; 2015 Dec; 34(4):797-805. PubMed ID: 26342831
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.
Byeon S; Ham JS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Med Oncol; 2016 Aug; 33(8):97. PubMed ID: 27447711
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.
Chuang JC; Neal JW; Niu XM; Wakelee HA
Lung Cancer; 2015 Oct; 90(1):1-7. PubMed ID: 26275476
[TBL] [Abstract][Full Text] [Related]
12. Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.
Zhang Q; Zhang X; Yan H; Jiang B; Xu C; Yang J; Chen Z; Su J; Wu YL; Zhou Q
Thorac Cancer; 2016 Nov; 7(6):648-654. PubMed ID: 27755835
[TBL] [Abstract][Full Text] [Related]
13. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
Costa DB; Shaw AT; Ou SH; Solomon BJ; Riely GJ; Ahn MJ; Zhou C; Shreeve SM; Selaru P; Polli A; Schnell P; Wilner KD; Wiltshire R; Camidge DR; Crinò L
J Clin Oncol; 2015 Jun; 33(17):1881-8. PubMed ID: 25624436
[TBL] [Abstract][Full Text] [Related]
14. A Neuro-oncologist's Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer.
McGranahan T; Nagpal S
Curr Treat Options Oncol; 2017 Apr; 18(4):22. PubMed ID: 28391420
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain.
Jamal-Hanjani M; Spicer J
Clin Cancer Res; 2012 Feb; 18(4):938-44. PubMed ID: 22167408
[TBL] [Abstract][Full Text] [Related]
16. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer.
Zhang J; Yu J; Sun X; Meng X
Cancer Lett; 2014 Aug; 351(1):6-12. PubMed ID: 24861428
[TBL] [Abstract][Full Text] [Related]
18. CNS Downstaging: An Emerging Treatment Paradigm for Extensive Brain Metastases in Oncogene-Addicted Lung Cancer.
Langston J; Patil T; Ross Camidge D; Bunn PA; Schenk EL; Pacheco JM; Jurica J; Waxweiler TV; Kavanagh BD; Rusthoven CG
Lung Cancer; 2023 Apr; 178():103-107. PubMed ID: 36809719
[TBL] [Abstract][Full Text] [Related]
19. Treatment options for EGFR mutant NSCLC with CNS involvement-Can patients BLOOM with the use of next generation EGFR TKIs?
Tan CS; Cho BC; Soo RA
Lung Cancer; 2017 Jun; 108():29-37. PubMed ID: 28625644
[TBL] [Abstract][Full Text] [Related]
20. Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?
Liao BC; Lin CC; Yang JC
Expert Opin Pharmacother; 2018 Jun; 19(8):851-864. PubMed ID: 29726292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]